Policy & Regulation
Cerveau Technologies to Support Massachusetts General Hospital Research Projects
12 February 2018 - - Boston, Massachusetts-based neurodegenerative disorders-focused diagnostics and technology developer Cerveau Technologies, Inc. has signed an agreement with Massachusetts General Hospital (MGH) to support multiple projects over the next several years, the company said.
These research projects are for studies of an early stage imaging agent (MK-6240) to be used in positron emission tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain.
NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer's disease.
As part of the agreement, Cerveau will contract with the Gordon Center for Medical Imaging, a research center and PET imaging facility within MGH, to manufacture and supply the [18F]MK-6240 needed for initiatives in the greater Boston area.
Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau's vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer's disease.